EPO and anemia (phenotype): To this end, recombinant Epo forms (epoetin-α, epoetin-β, and the long-acting analogue darbepoetin-α) have been used to treat anemia in chronic kidney disease and chemotherapy-induced anemia in cancer patients [3].